Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAH vs VA in Relapsed/Refractory AML
NCT05457361Phase 3Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Mar 2022
- Primary completion
- Dec 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of homoharringtonine in acute myeloid leukemia (AML) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Overall Response Rate at Cycle 2. Status: unknown.
02
Drugs
homoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05457361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05457361.